FPRT Bio is an emerging, clinical stage drug developer currently working on a new anti-inflammatory treatment for a wide range of neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, and ALS. In an effort to further develop the company’s exposure in the industry and build new partnerships with the biotech and patient communities, FPRT recently announced that it will participate in this year’s Cavendish Global Health Impact Forum, which runs from May 5th to 7th in New York City.
The Forum’s aim is to bridge a gap between family offices and foundations in order to foster several critical support channels for life sciences research, such as individual pro-social impact investing, philanthropy programs, and the grant-giving process. Given Cavendish Global’s global network of over 150 leading family offices and fundraising foundations, and over $190 billion in combined assets, the organization is well positioned to successfully lead such an endeavor. In order to accomplish the Forum’s mission this year, FPRT will collaborate with event leaders and sponsors to highlight informative presentations and panel discussions led by an interdisciplinary team of influencers within the sector, including top researchers, proven healthcare business professionals, experts in health-policy, and other private-sector companies that are actively engaged in investing in and advancing innovations aimed at furthering prevention, diagnosis and treatment of the world’s most deadly and debilitating diseases.
Cavendish co-founder and President Michael Moffat noted how FPRT’s participating in the Forum this year will have a palpable impact on the event’s success, explaining that, “With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence.” FPRT was an obvious choice for this year’s forum: “The quality and originality of FPRT Bio research and scientific insights in neurodegenerative diseases including ALS, Parkinson’s and Alzheimer’s disease positions them to make a major contribution to treating the cause of these devastating neurologic diseases.”
RJ Tesi, MD, President and CEO of FPRT, sees a unique opportunity for his emerging company to make major inroads into accelerating a cure for neurodegenerative diseases through its partnership with Cavendish: “We are honored to be selected to present at this unique event, and it is further recognition of our innovative approach to attack chronic neuroinflammation, a major cause of neurodegenerative diseases such as ALS and Alzheimer’s disease,” he said. “These devastating neurologic diseases have no cure, cause incalculable suffering by patients and place tremendous burdens on families and payers. We welcome the chance to interact with many of world’s leading scientific minds, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world.”
The Forum will also provide an excellent platform for FPRT Bio to showcase more insights into its lead experimental therapy, XPro1595, which, according to the company, is “a novel, second-generation, selective inhibitor of soluble TNF for the treatment of neurodegenerative diseases including ALS, Parkinson’s and Alzheimer’s disease.” The company believes that XPro1595’s potential potency and efficacy lies in its ability to successfully cross the blood-brain-barrier — a natural barrier that often makes it difficult for therapies to treat the brain — and doing so, can effectively decrease inflammatory cytokine production through activated microglial cells and astrocytes. FPRT goes on to explain in a recent press release that, “By polarizing the complex TNF biology of the brain to trans-membrane TNF effects, XPro1595 is neuroprotective, promotes remyelination and improves neuroplasticity. This unique biology and pharmacology makes XPro1595 ideally suited for treating these devastating neurologic diseases. FPRT Bio is raising a Series A to support Proof-of-Biology clinical trials in two indications – ALS and Alzheimer’s disease. FPRT Bio, which has ties to the Dallas-Fort Worth area, has received a grant from The Michael J. Fox Foundation for Parkinson’s Research to research a novel therapeutic strategy to treat Parkinson’s disease.”
To find out more about the Forum, be sure to visit the Cavendish Global website here: http://cavendishglobal.com